NCT01941771 - Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions

Breast Cancer

Interventions

DRUG

Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)

Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.

DRUG

Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)

Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.

Trial Locations (1)

8000

Department of Oncology, Aarhus University Hospital, Aarhus